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Overview of Pharmacovigilance Practices at the Largest Academic 1 
Healthcare System in the State of Qatar 2 
Introduction  3 
Pharmacovigilance (PV) plays a vital role to ensure patient safety. The World 4 
Health Organization (WHO) defines ‘pharmacovigilance’ as a process of 5 
detection, monitoring and preventing drug-related harm [1]. Adverse Drug 6 
Reaction (ADR) reporting is the cornerstone of PV. The WHO defines ADR as 7 
“a response to a drug which is noxious and unintended, and which occurs at 8 
doses normally used in man for the prophylaxis, diagnosis, or therapy of 9 
disease, or for the modification of physiological function” [2].   10 
ADRs are major global issue, adversely impacting patient safety and health 11 
outcomes; they are ranked as fourth and seventh leading cause of death in 12 
United States and Sweden, respectively [3,4]. Due to significant under-13 
reporting and vast heterogeneity in the use of definitions, data collection 14 
methods, the incidence and prevalence of ADRs vary considerably across 15 
countries, ranging from 16% among studies performed in United Kingdom 16 
(UK) [5] to 38% in Germany [6], 6% in South Africa [7], to 4.5% and 10.2% 17 
among studies performed in Saudi Arabia [8] and United Arab Emirates 18 
(UAE) [9]. A meta-analysis (1998) to determine the incidence of ADRs 19 
among hospitalized patients suggested that ADRs affected over 2 million 20 
patients at an estimated cost of $130 billion annually in the United States 21 
(US) alone [10].  22 
PV practices in Qatar are evolving rapidly and ADR reporting systems have 23 
undergone significant changes over the last few years. Despite all the recent 24 
developments, there is scarcity of published evidence relating to ADR 25 
reporting in Qatar. This article explores organizational structure, PV practices 26 
and provides information about how ADRs are identified, reported, analyzed 27 
and interpreted at a healthcare level. It also provides blueprint of a 28 
Medication Safety Center at the largest academic healthcare system in Qatar.  29 
 30 
Healthcare system in Qatar 31 
 32 
Qatar is a small peninsula occupying 11,437 km2 of land area and has a total 33 
population of 2.6 million, of which only 15% are native Qataris [11]. The 34 
quality of healthcare delivery in Qatar is of very high standards with annual 35 
healthcare budget exceeding $3,071 per capita (2.2% of GDP) in 2014, one 36 
of the highest in the region. The Ministry of Public Health (MoPH) is Qatar’s 37 
highest health authority, responsible to plan and advise on the national 38 
healthcare priorities, to regulate and monitor healthcare systems and provide 39 
services to meet the national healthcare needs. Unlike other high-income 40 
countries where people are the main source of healthcare funding, healthcare 41 
costs in Qatar are predominantly financed by government revenues, by 42 
providing free treatment to the nationals and heavily subsidized treatment 43 
options to the residents [12].  44 
Under the regulation of MoPH, the healthcare system in Qatar is primarily 45 
divided into private and public healthcare sectors. The current structure of 46 
healthcare services can be found in Figure 1.  47 
 48 
Figure 1: Qatar Healthcare System (information retrieved from MoPH website) 49 
National Health Strategy 2011-2016 50 
Improving patient safety through ‘safe use of medication’ is a core 51 
component of Qatar’s National Health Strategy (NHS) 2011-2016 [14]. NHS 52 
advocates developing a world-class healthcare system by ensuring safe and 53 
effective use of medications and healthcare products. Establishing a 54 
specialized Medication Safety & Quality Center (MSQC) at Hamad Medical 55 
Corporation (HMC), the tertiary and academic healthcare provider within 56 
MoPH, to monitor the safe and effective use of medications, is one of the key 57 
strategies to achieve the goals set by the NHS.  58 
Establishing HMC’s Medication Safety & Quality Centre (MSQC) 59 
Since 2016, MSQC is recognized as a center to monitor medication safety 60 
practices within HMC, which in turn created a community of medication 61 
safety experts within the healthcare system.  62 
How it started? 63 
To better understand the nature and scope of medication-related harm, 64 
improve the current medication safety practices, and further strengthen the 65 
PV activities, the pharmacy leadership at HMC established a corporate clinical 66 
unit called MSQC. Qatar is an associate member of WHO Program for 67 
International Drug Monitoring, and a national center exists at MoPH, where 68 
majority of ADR data originates from HMC.   69 
Mission 70 
MSQC is committed to develop interventions to reduce medication errors, 71 
prevent and manage Adverse Drug Events (ADEs) and encourage safe 72 
medication use practices across HMC. MSQC has established a methodical 73 
ADR reporting, monitoring, and analyzing system at HMC.   74 
 75 
Blueprint  76 
Establishing MSQC require great effort, dedication, proficiency and regular 77 
follow-up. Setting up the center demands an organizational framework, 78 
recruiting and training Medication Safety Officers (MSOs), and designing the 79 
reporting system. MSQC was structured to detect and monitor all PV 80 
activities within HMC. MSQC comprises of 11 MSOs (one from each HMC 81 
facility), a coordinator, and three administrative staff (Co-Head, Head and 82 
Chair) sharing other responsibilities within HMC.  83 
ADR Reporting Policy 84 
HMC has adopted WHO definition of ADRs. ADR reporting at HMC is policy-85 
driven and has migrated from a paper-based system to an electronic system 86 
(Cerner®). HMC’s policy on suspected ADR reporting and monitoring requires 87 
all ADRs to be documented in patients’ medical records and to be reported 88 
immediately. However, data about the quality, nature and extent of these 89 
reports are lacking. Anecdotal evidence indicates that healthcare 90 
professionals have different attitudes and affinities to document and report 91 
ADRs and there are possibilities of gross under-reporting. 92 
ADR Reporting & Data Acquisition at HMC 93 
 94 
The ADR reporting process at HMC is centralized, whereby all suspected 95 
ADRs are reported by HCPs (mostly pharmacists, nurses and doctors) 96 
electronically. Any drug related problem that implies a causal relation 97 
between the drug and the adverse reaction must be reported, with details 98 
about the drug, reaction, timings and interventions. The ADR reporting 99 
process at HMC is illustrated in Figure 2.  100 
Figure 2: ADR reporting process at HMC 101 
Reports are then reviewed by the hospital specific MSOs and are further 102 
classified based on causality, severity, and preventability using different tools 103 
(Causality - Naranjo Causality Scale, Severity - Hartwig’s Severity Scale, 104 
Preventability - Schumock and Thornton Preventability). Once completed, 105 
these reports are forwarded to the corporate office (MSQC), where the 106 
reports are reviewed and pooled for any potential causal relationship. MSQC 107 
generates a monthly report to the pharmacy executive director who then 108 
disseminates the findings to MoPH, Quality and Patient Safety Committee 109 
(QPS), Risk Management Committee and other key stakeholders (Qatar 110 
University, patient safety departments etc.,)for further actions. Furthermore, 111 
all clinically relevant ADRs are disseminated to healthcare professionals 112 
(HCPs) through presentations, discussions and monthly newsletters. The 113 
dissemination of such information leads to institutional and individual 114 
learning and a continuous improvement of patient safety and change in 115 
practice.  116 
Memberships and Affiliations  117 
HMC is the only academic health system outside the US to have all its 118 
hospitals accredited by the Joint Commission International (JCI), 119 
demonstrating its commitment to continuous delivery of safe, high-quality 120 
care [15].  Moreover, in collaboration with the Institute for Healthcare 121 
Improvement (IHI), HMC is committed to provide the safest, most effective 122 
and most compassionate care to each and every patient [16]. MSQC within 123 
HMC is a full member of the International Medication Safety Network (IMSN), 124 
an international organization committed to prevent medication-related harm 125 
and contribute to safer healthcare [17]. Qatar is also an associate member 126 
[reports are not shared with the global PV community (WHO database) and 127 
will no add to any international signal analysis or learning outside of Qatar] 128 
of the WHO Program for International Drug Monitoring [18].  129 
Number and Nature of ADR Reports 130 
MSQC analyzed 1599 ADRs that were reported across HMC between January 131 
2016 and December 2017. A wide variation in reporting rates was observed 132 
among different hospitals; National Cancer Center=372 ADRs, Heart 133 
Hospital=167, Hamad General Hospital=345, Women’s Hospital=231, Al-134 
Khor Hospital=77, Rumailah Hospital=97, Cuban Hospital=63, Communicable 135 
Disease Center=19, Al-Wakra Hospital=142, Mental Health Hospital=42, and 136 
Home Healthcare Service=44). As illustrated in Table 1, approximately 92% 137 
of reported ADRs were ‘mild–moderate’ in severity scale, whilst less than 9% 138 
were ‘severe’. Nearly 88% were ‘non-preventable’. Majority of ADRs were 139 
reported by pharmacists (57.3%).  140 
Table 1: Assessment of ADR reports at HMC 141 
 142 
Detection and Management  143 
Individual case reports of suspected ADRs are the primary source of data to 144 
detect the unexpected harm caused by medications. This information is vital 145 
to effectively manage and reduce the severity of harm due to medications. 146 
 147 
Spontaneous reporting system at HMC facilitates timely detection of unknown 148 
ADRs. The process of ADR detection or causal relationship between the 149 
suspected drug and the ADR is usually carried out by means of a methodical 150 
manual review of all ADR reports submitted using qualitative methods (case 151 
analysis). However, spontaneous nature of reporting also possess few 152 
limitations, e.g. some complex associations between patient demographics 153 
and reported reactions are not always true while fear of consequences also 154 
lead to underreporting of serious ADRs.  155 
Examples of qualitative – case analysis at HMC,  156 
 A case of probable piperacillin/tazobactam-induced bone marrow 157 
suppression in a pregnant woman (ElSalem S, et.al, 2017) 158 
 A case of probable esomeprazole-induced transient liver injury in a 159 
pregnant woman with hyperemesis (Thomas B, et.al, 2016) 160 
 A case of probable labetalol induced hyperkalemia in pre-eclampsia. 161 
(Thomas B, et.al, 2014) 162 
Good PV Practices and Risk Reduction Strategies 163 
A set of measures have been developed by MSQC to facilitate and enhance 164 
the PV practices at HMC: All healthcare professionals joining HMC are 165 
scheduled for a mandatory medication safety educational session. Other 166 
activities include  167 
 Encourage, educate and support healthcare professionals and patients 168 
to report all suspected ADRs; 169 
 Review the reports for accuracy and completeness;  170 
 Raise awareness about the importance of proper documentation; 171 
 Provide feedback to the reporters; 172 
 Maintain the confidentiality of data about the reporter and patient; 173 
 Assess benefit-to-risk ratio; 174 
 Provide medication safety updates and recommendations through a 175 
monthly newsletter; 176 
 Follow the standards and policies set by the MoPH, Qatar. 177 
These initiatives have improved the medication safety practices at HMC 178 
resulting in changes in policies of look-alike sound-alike drugs, use of high-179 
alert medications, label change for neuromuscular blockers etc. 180 
 181 
Challenges  182 
Despite the substantial progress made over the last few years, PV systems 183 
across the world still face a number of challenges with underreporting being 184 
one of them. It often delays the response process such as changing labels, 185 
issuing warnings and withdrawing drugs, and thereby compromising patient 186 
safety. Factors contributing to underreporting include most notably 187 
ignorance, lack of interest or time to report, fear of consequences, judgment 188 
bias, and belief that all drugs in the market are safe. [19]  189 
A questionnaire-based study [20] to assess the knowledge, attitude, and 190 
barriers to ADR reporting among pharmacists in HMC revealed that although 191 
majority of pharmacists showed positive attitude towards ADR reporting, a 192 
considerable number exhibited lack of knowledge about ADRs, how to report, 193 
and what to report. Approximately 60% of the pharmacists responded did 194 
not report any ADR over the previous 12 months, mostly due to lack of time, 195 
busy schedule, cultural issues, and lack of awareness about what to report. 196 
Pharmacists also revealed that they did not receive any feedback to their 197 
previous reports, discouraging to report future incidents. Poor knowledge and 198 
lack of engagement of general public and patients towards PV practices were 199 
also among the challenges noted during the study. The findings were similar 200 
to what has been reported in other studies from the region and further afield 201 
[19, 21-23]. Hence, strategies need to be focused towards creating 202 
awareness among pharmacists about ADRs and importance of reporting.  203 
Conclusion  204 
Clear understanding of the characteristics and knowledge of patient safety 205 
practices are cornerstone to PV activities. As in other developing countries, 206 
PV in Qatar is evolving rapidly. Spontaneous reporting, transparency and 207 
active surveillance are new advancements in the reporting system at HMC. 208 
Further developments aim at automatic signal generation, patient reporting, 209 
and educational interventions to healthcare professionals and patients, to 210 
enhance the quality of ADR reports. 211 
Funding  212 
No funding was received for this paper.  213 
Conflict of Interest  214 
All the authors declare that they have no conflict of interest.  215 
References  216 
(1) World Health Organization. Reporting and learning systems for medication 217 
errors: the role of pharmacovigilance centers. 2014. Available from: 218 
http://apps.who.int/medicinedocs/documents/s21625en/s21625en.pdf Accessed 05 219 
February, 2018 220 
(2) World Health Organization. International drug monitoring: the role of the 221 
hospital, report of a WHO meeting [held in Geneva from 18 to 23 November 1968]. 222 
1969. Available from: 223 
http://apps.who.int/iris/bitstream/10665/40747/1/WHO_TRS_425.pdf Accessed 05 224 
February, 2018 225 
(3) Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the 226 
United States, 1970-2002. JAMA. 2005; 294(10):1255-1259. 227 
(4) Wester K, Jönsson AK, Spigset O, Druid H, Hägg S. Incidence of fatal adverse 228 
drug reactions: a population based study. British Journal of Clinical Pharmacology. 229 
2008; 65(4):573-579. 230 
(5) Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. 231 
Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 232 
patient-episodes. PLoS One. 2009; 4(2):e4439. 233 
(6) Zopf Y, Rabe C, Neubert A, Hahn EG, Dormann H. Risk factors associated with 234 
adverse drug reactions following hospital admission. Drug Safety. 2008; 31(9):789-235 
798. 236 
(7) Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI. Adverse 237 
drug reactions in adult medical inpatients in a South African hospital serving a 238 
community with a high HIV/AIDS prevalence: prospective observational study. 239 
British Journal of Clinical Pharmacology. 2008; 65(3):396-406. 240 
(8) Khan LM, Al-Harthi S, Saadah OI. Adverse drug reactions in hospitalized pediatric 241 
patients of Saudi Arabian University Hospital and impact of pharmacovigilance in 242 
reporting ADR. Saudi Pharmaceutical Journal: 2013; 21(3):261-266. 243 
(9) Sridhar SB, Al-Thamer SSF, Jabbar R. Monitoring of adverse drug reactions in 244 
psychiatry outpatient department of a Secondary Care Hospital of Ras Al Khaimah, 245 
UAE. Journal of Basic and Clinical Pharmacy. 2016;7(3):80. 246 
(10) Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in 247 
hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 248 
279(15):1200-1205. 249 
(11) Ministry of Development Planning and Statistics. Total Population within the 250 
State of Qatar. 2017. Available from: 251 
http://www.mdps.gov.qa/portal/page/portal/gsdp_en/statistics_en/monthly_prelimin252 
ary_figures_on_population_en. Accessed 10 January, 2018  253 
(12) Ministry of Public Health (MoPH) Qatar. Health Objectives: Ministry of Public 254 
Health; 2017 Available from: https://phs.moph.gov.qa/current-status/. Accessed 10 255 
January,2018  256 
(13) Ministry of Public Health, Qatar. Health Services. 2018. Available from: 257 
https://www.moph.gov.qa/health-services/Pages/default.aspx Accessed 22 January, 258 
2018 259 
(14) National Health Strategy 2011-2016. Healthcare products regulation. General 260 
Secretariat, Supreme Council of Health; 2014. Available from:  261 
www.nhsq.info/strategy-goals-and./national-health/healthcare-products-regulation 262 
Accessed 10 January, 2018 263 
(15) Joint Commission International (JCI). JCI-Accredited Organizations. Available 264 
from: https://www.jointcommissioninternational.org/about-jci/jci-accredited-265 
organizations/?c=Qatar. Accessed 19 December, 2017  266 
(16) The Institute for Healthcare Improvement. Current Collaborations in the Region 267 
- Qatar - Hamad Medical Corporation. Institute for Healthcare Improvement.  268 
Available from: http://www.ihi.org/regions/MiddleEast/Pages/OurWork.aspx. 269 
Accessed 10 January, 2018 270 
(17) International Medication Safety Network (IMSN). Medication Safety & Quality 271 
Center (MSQC): Qatar. 2018. Available from: 272 
https://www.intmedsafe.net/about/imsn-members/ . Accessed 10 January, 2018. 273 
(18) WHO Program for International Drug Monitoring. Associate Members: Qatar. 274 
2018. Available from: https://www.who-umc.org/global-275 
pharmacovigilance/members/who-programme-members/ . Accessed 10 January, 276 
2018. 277 
(19) Steurbaut S, Hanssens Y. Pharmacovigilance: empowering healthcare 278 
professionals and patients. International Journal of Clinical Pharmacy. 2014; 279 
36(5):859-862. 280 
(20) ElKassem W, Al Hail M, Rouf A, Hamad A, Thomas B. An evaluation of 281 
knowledge, attitude and practice of pharmacists towards adverse drug reactions: a 282 
questionnaire based study at Hamad Medical Corporation, Qatar. 4th December. 283 
2017. Available from: 284 
https://www.eventscribe.com/2017/ASHPMeeting/ajaxcalls/PosterInfo.asp?efp=WUF285 
ORk1KUU8yMDk5&PosterID=117702&rnd=0.5433606. Accessed 10 January, 2018. 286 
(21) Almandil NB. Healthcare professionals' awareness and knowledge of adverse 287 
drug reactions and pharmacovigilance. Saudi Medical Journal. 2016; 37(12):1359-288 
1364. 289 
(22) Alshammari TM, Alamri KK, Ghawa YA, Alohali NF, Abualkol SA, Aljadhey HS. 290 
Knowledge and attitude of health-care professionals in hospitals towards 291 
pharmacovigilance in Saudi Arabia. International Journal of Clinical Pharmacy. 2015; 292 
37(6):1104-1110. 293 
(23) Hajebi G, Mortazavi SA, Salamzadeh J, Zian A. A Survey of Knowledge, Attitude 294 
and Practice of Nurses towards Pharmacovigilance in Taleqani Hospital. Iranian 295 
Journal of Pharmaceutical Research: IJPR. 2010; 9(2):199-206. 296 
 297 
 298 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Qatar Healthcare System (information retrieved from MoPH website) 
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Figure 2: ADR reporting process at HMC 
 
Spontaneous ADR 
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(electronic system) 
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provides necessary 
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reporters 
Reports are then classified 
and analyzed based on 
preventability, severity, and 
causality using validated 
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MSQC (Corporate) receives, 
collates and reviews the 
facility reports. Evaluate 
the reports for quality, 
clarity, quantity and 
SIGNAL detection 
Corporate Pharmacy ED 
then disseminates the 
findings to, HMC‐ QPS & 
Risk Management, MoPH 
and other stakeholders 
for further actions 
Clinically significant ADRs 
are disseminated to HCPs 
through presentations and 
newsletters and later 
followed up and 
monitored  
 
ADR – Adverse Drug Reactions, MSO – Medication Safety Officers, MSQC – Medication Safety & Quality Center,             
ED – Executive Director, QPS – Quality and Patient Safety, MoPH – Ministry of Public Health, HCP – Healthcare 
Practitioners 
 
Table 1: Assessment of ADR reports at HMC 
Assessment Category No. of ADRs (%)  n=1599 
Causality (Naranjo’s 
Scale) 
Definite 94 (5.8) 
Probable 799 (49.9) 
Possible 690 (43.1) 
Doubtful 16 (1.0) 
Preventability 
(Hartwig’s Scale) 
Not Preventable 1406 (87.9) 
Probably Preventable 175 (10.9) 
Definitely Preventable 18 (1.1) 
Severity  
(Schumock & 
Thornton’s Scale) 
Mild 764 (47.7) 
Severe 113 (7.0) 
Moderate 722 (45.1) 
Reported by 
Pharmacist 913 (57) 
Nurse 556 (34.7) 
Doctor 130 (8.1) 
